Pfizer PFE Biopharma — Restructuring cost incurred to date

Similar metrics at other companies

MATVFAM — Restructuring incurred to date

$12.7M+15.5%

CPBCorporate — Restructuring and Related Cost, Cost Incurred to Date

$34M+183%

CPBSnacks — Restructuring and Related Cost, Cost Incurred to Date

$52M+420%

ULSConsumer — Restructuring and Related Cost, Cost Incurred to Date

$27M—

ULSIndustrial — Restructuring and Related Cost, Cost Incurred to Date

$8M—

KMTInfrastructure — Restructuring and related cost, cost incurred to date

$5.5M0.0%

FAQ

What is Pfizer's biopharma — restructuring cost incurred to date?

Pfizer (PFE) reported biopharma — restructuring cost incurred to date of $3.3B in Q1 2026.

How has Pfizer's biopharma — restructuring cost incurred to date changed year-over-year?

Pfizer's biopharma — restructuring cost incurred to date increased by 22.2% year-over-year, from $2.7B to $3.3B.

What is the long-term trend for Pfizer's biopharma — restructuring cost incurred to date?

Over 3 years (2022 to 2025), Pfizer's biopharma — restructuring cost incurred to date has grown at a 38.1% compound annual growth rate (CAGR), from $4.36B to $11.5B.

What does biopharma — restructuring cost incurred to date mean?

The cumulative financial impact of restructuring activities already executed within the biopharmaceutical segment. It reflects the actual cash or non-cash charges recognized on the income statement due to organizational realignment.